In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer.

Nat Genet
Authors
Keywords
Abstract

Detection of minor, genetically distinct subpopulations within tumors is a key challenge in cancer genomics. Here we report STAR-FISH (specific-to-allele PCR-FISH), a novel method for the combined detection of single-nucleotide and copy number alterations in single cells in intact archived tissues. Using this method, we assessed the clinical impact of changes in the frequency and topology of PIK3CA mutation and HER2 (ERBB2) amplification within HER2-positive breast cancer during neoadjuvant therapy. We found that these two genetic events are not always present in the same cells. Chemotherapy selects for PIK3CA-mutant cells, a minor subpopulation in nearly all treatment-naive samples, and modulates genetic diversity within tumors. Treatment-associated changes in the spatial distribution of cellular genetic diversity correlated with poor long-term outcome following adjuvant therapy with trastuzumab. Our findings support the use of in situ single cell-based methods in cancer genomics and imply that chemotherapy before HER2-targeted therapy may promote treatment resistance.

Year of Publication
2015
Journal
Nat Genet
Volume
47
Issue
10
Pages
1212-9
Date Published
2015 Oct
ISSN
1546-1718
URL
DOI
10.1038/ng.3391
PubMed ID
26301495
PubMed Central ID
PMC4589505
Links
Grant list
P30 CA008748 / CA / NCI NIH HHS / United States
U54 CA143798 / CA / NCI NIH HHS / United States
U54CA143798 / CA / NCI NIH HHS / United States